General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, in adult patients who are not eligible for autologous stem cell transplant & have received at least one prior therapy (In combination with bendamustine & rituximab)
Last updated December 1, 2021
Duobrii (Halobetasol propionate and tazarotene)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated November 30, 2021
Status:
Negotiations were not pursued
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Chronic weight management
Last updated November 22, 2021
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Severe Hypoglycemia
Last updated November 22, 2021
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT
Last updated November 18, 2021
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Heart failure, NYHA class II or III
Last updated November 18, 2021
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC
Indication:
Metastatic colorectal cancer (mCRC), locally advanced, metastatic or recurrent non-small cell lung Cancer (NSCLC), platinum-resistant recurrent epithelial ovarian, fallopian tube and primary peritoneal cancer, and glioblastoma
Last updated October 25, 2021
Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Secondary Progressive Multiple Sclerosis (SPMS)
Last updated October 22, 2021
Tecentriq & Avastin (Atezolizumab & Bevacizumab)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Unresectable or metastatic hepatocellular carcinoma (HCC) in adult patients who require systemic therapy
Last updated October 14, 2021
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Last updated October 14, 2021